Report Overview

The global vitiligo treatment market was pegged at US$ 1.42 billion in 2021 and is expected to witness a CAGR of 6.14% during the forecast period.

Market Fundamentals

Vitiligo or leucoderma is a skin disorder caused due to development of light white spots on the skin, due to lack of melanin. Vitiligo can affect many areas of skin, but it generally affects face, neck, skin creases and hands. Vitiligo occurs due to breakdown of pigment producing cells called melanocytes. Vitiligo can develop at any age; it generally appears before the age of 30. There are two main type of vitiligo segmental and non-segmental. 

Market Dynamics

[326839]

The primary drivers propelling the global vitiligo treatment market is the growing prevalence of vitiligo due to genetic factors; furthermore, major skin problems such as sunburn and exposure to strong chemicals and Increasing development of innovative drugs. 

On the other hand, concerns over branded drugs patent expiration and the high cost of diagnosing and treating vitiligo are predicted to impede market growth. 

Market Ecosystem

The global vitiligo treatment market has been analyzed from four perspectives: treatment, disease type, end-user, and Region. 

Global Vitiligo Treatment Market By Treatment

[123674]

According to treatment the global market for vitiligo treatment is segmented into topical treatment, surgical procedure, and light therapy. The light treatment segment has dominated the market, and touted as one of the best conventional vitiligo treatments. The UV rays from light treatment stimulates the body's production of vitamin D, which may cause the skin to depigment. This therapy is more effective when used with corticosteroids or calcineurin inhibitors. The best treatment for vitiligo patients currently available is nbUVB (narrow-band ultraviolet light B). This treatment is generally safe, but it takes time because it is typically done in a dermatologist's clinic for two to three times each week. Other segments like surgical procedures and topical treatments are also expected to show high growth in the forecast period. Surgical treatments offer a potential to treat significant areas of hypopigmentation in relation to the skin fragment obtained for the transplant. Topical treatment segment is first line of treatment offered for this condition the anti-inflammatory drugs called corticosteroid creams may break the growth of vitiligo or allow melanocytes to grow again. Dermatologists regularly monitor corticosteroid use when it is administered because vitiligo requires a powerful corticosteroid combination.

Global Vitiligo Treatment Market by Disease Type 

Based on disease type, the global vitiligo market is segmented into segmental vitiligo and non-segmental vitiligo. Non segmental vitiligo is the most common type. It is believed that non-segmental vitiligo is an autoimmune disease and can spread very rapidly. In addition, according to the Indian Dermatology Online Journal a cross-sectional study was conducted among 200 patients with vitiligo, the study states that 33 individuals (16.5%) had segmental vitiligo, while 167 (83.5%) had non-segmental vitiligo. The study also concluded that after the condition has been stable for two years, segmental vitiligo typically reaches to reduction. Whereas, even after extended intervals of stability, non-segmental vitiligo is prone to reactivation.  

Global Vitiligo Treatment Market by Region 

Regionally, the global vitiligo treatment market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. In terms of market share, North America has dominated the market. This growth is being attributed to the incidence of adult vitiligo in this area, increased awareness, and the existence of several market players. In addition, survey research discovered that between 0.76% and 1.11% i.e., between 1.9 million and 2.8 million instances. The presence of reimbursement activities also supports the region. For instance, the Global Vitiligo Foundation, based in the United States, gives coverage of the necessary therapy, through counselling, research, professional care, and community support, the program primarily focuses on enhancing the quality of life for people with vitiligo. A large patient population and a significant number of clinical trials exist, over the forecast period, Asia Pacific is anticipated to experience tremendous growth. Clinical studies have led to the approval of many pharmaceuticals in this region, which will eventually increase the global market. 

Competitive Landscape

Some of the prominent players operating in the global vitiligo treatment market are 

• Incyte Corporation
• Astellas Pharma Inc. 
• Baxter International Inc. 
• Dr. Reddy’s Laboratories Ltd. 
• Pfizer Inc. 
• Sanofi SA
• Teva Pharmaceutical Industries
• GlaxoSmithKline Plc
• F. Hoffman La Roche AG
• Eli Lilly and Company 
• Bausch Health Companies Inc. 
• STRATA Skin Sciences
• Dermavant Sciences, Inc.
• Aclaris Therapeutics Inc.
• Bristol - Myers Squibb
• Eli Lilly and Company 

Strategic Developments

• In July 2022, the first drug Opzelura to target repigmentation in vitiligo patients received FDA (Food and Drug Administration) approval. Up to 10% of the surface area of the can be treated with this drug. If the patient's response is satisfactory, Opzelura treatment may last for more than 24 weeks.
• In May 2019, Ruxolitinib (JAKAFI, Incyte Corporation) received FDA approval to treat adults and kids aged 12 years and older with acute graft-versus-host disease (GVHD) that is steroid-refractory.

Frequently Asked Questions About This Report